Result of General Meeting

 

TIDMIBL 
 
RNS Number : 7368O 
International Brand Licensing PLC 
02 July 2010 
 
 
+-+---------------------------------------------------------+----------+ 
| |    International Brand Licensing plc ("IBL" or "the     |          | 
| |                        Company")                        |          | 
+-+---------------------------------------------------------+----------+ 
 
                            Result of General Meeting 
 
International Brand Licensing Plc (AIM: IBL), a growing business within the 
in-vitro diagnostic devices market, is pleased to announce that at the General 
Meeting held earlier today all resolutions were duly passed. The passing of the 
resolutions will enable the Company to proceed with: 
 
·    The acquisition of EKF-diagnostic GmbH which is conditional, inter alia, on 
Admission of the Placing Shares. 
 
·    The allotment of the Placing Shares, to raise gross proceeds of 
approximately GBP15.06 million, the admission of which will take place in three 
stages: 
 
o  In the First Admission, 10,666,665 new ordinary shares of 1p each will be 
admitted to trading. The Company has made an application to the London Stock 
Exchange and it is expected that First Admission will take place on 5 July 2010; 
 
o  In the Second Admission, a further 25,499,998 new ordinary shares of 1p each 
will be admitted to trading. The Company has made an application to the London 
Stock Exchange and it is expected that Second Admission will take place on 6 
July 2010; and 
 
o  In the Third Admission, a further 64,268,990 new ordinary shares of 1p each 
will be admitted to trading and all of the Existing Ordinary Shares will also be 
readmitted to trading. The Company has made an application to the London Stock 
Exchange and it is expected that Third Admission will take place on 7 July 2010. 
 
·     The Change of Name of the Company to EKF Diagnostics Holdings plc, which 
will be effective (for the purposes of AIM) from 7 July 2010 (AIM trading symbol 
will be EKF.L). 
 
Definitions in this announcement are consistent with those set out in the 
Admission Document issued to shareholders of the Company and dated 15 June 2010, 
a copy of which is available on the Company's website. 
 
Julian Baines, CEO of EKF Diagnostics Holdings plc commented: "The acquisition 
of EKF-diagnostic GmbH is the first step in our strategy to build a diagnostics 
business and gives us a good platform for future growth both organically and by 
further acquisitions. We intend, in particular, to focus on devices and reagents 
relating to diabetes, one of the fastest growing diseases in the world." 
 
Enquiries: 
 
+---------------------------------------+------------------------------+ 
| International Brand Licensing plc     |                              | 
+---------------------------------------+------------------------------+ 
| Julian Baines, CEO                    |           Mob: [phone] | 
+---------------------------------------+------------------------------+ 
| Paul Foulger, Finance Director        |           Tel: [phone] | 
+---------------------------------------+------------------------------+ 
|                                       |                              | 
+---------------------------------------+------------------------------+ 
| Zeus Capital (Nominated Adviser and   |           Tel: [phone] | 
| Joint Broker)                         |                              | 
+---------------------------------------+------------------------------+ 
| Ross Andrews / Tom Rowley             |                              | 
+---------------------------------------+------------------------------+ 
|                                       |                              | 
+---------------------------------------+------------------------------+ 
| Matrix Corporate Capital LLP (Joint   |           Tel: [phone] | 
| Broker)                               |                              | 
+---------------------------------------+------------------------------+ 
| Robert Naylor / Stephen Waterman      |                              | 
+---------------------------------------+------------------------------+ 
|                                       |                              | 
+---------------------------------------+------------------------------+ 
| Walbrook PR                           |           Tel: [phone] | 
+---------------------------------------+------------------------------+ 
| Paul McManus / Ben Knowles            |   [e-mail] | 
+---------------------------------------+------------------------------+ 
 
 
Notes to editors 
 
Details of acquisition and placing 
 
In the announcement on 15 June 2010 IBL announced: 
 
·    an agreement to acquire EKF-diagnostic GmbH ("EKF") for a total 
consideration of EUR14.32m to be satisfied by EUR11.32m in cash on completion and 
EUR3m deferred consideration in shares; and 
·    a placing to raise approximately GBP15.06m (gross) by means of the issue of 
100,435,653 new Ordinary Shares at 15 pence per share to fund the acquisition 
and to provide working capital 
 
About EKF Diagnostics Holdings plc 
 
The acquisition of EKF-diagnostic GmbH ("EKF") has provided the Company with an 
established, profitable and cash generative business within the diagnostic 
devices industry. The Enlarged Group will be a manufacturer and distributor of 
point of care diagnostic devices and reagents and will immediately have sales 
and distribution channels into over 65 countries (including the key markets of 
the US, Europe and Russia). 
 
About EKF 
 
EKF, based in Barleben, Germany, was founded in 1990 and focuses on the 
development, manufacture and selling of diagnostic instruments and reagents to 
clinical and research laboratories, doctors' offices and sports medicine testing 
sites worldwide. EKF focuses on diabetes and anaemia testing, two of the main 
segments of the point of care market. 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 REGFLLFBBDFFBBF